UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talks to Prof. Morgan Roupret (FR), on the results of the ALBAN trial. A phase 3, randomised, open-label, international study of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) vs BCG alone in BCG naïve high-risk, non-muscle invasive bladder cancer.
This interview was recorded at ESMO 2025 in Berlin, Germany. For more updates on bladder cancer, please visit our educational platform UROONCO BCa.
For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.
Published on 6 days, 11 hours ago
If you like Podbriefly.com, please consider donating to support the ongoing development.
Donate